These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20381925)

  • 1. [Pharmacokinetic and pharmacodynamic aspects of interpretive reading of the antibiogram].
    Soriano-García F
    Enferm Infecc Microbiol Clin; 2010; 28(7):461-6. PubMed ID: 20381925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
    McKellar QA; Sanchez Bruni SF; Jones DG
    J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis.
    Burgess DS; Frei CR; Lewis Ii JS; Fiebelkorn KR; Jorgensen JH
    Clin Microbiol Infect; 2007 Jan; 13(1):33-9. PubMed ID: 17184285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints.
    Ambrose PG
    Treat Respir Med; 2005; 4 Suppl 1():5-11. PubMed ID: 15846151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices.
    Barbour A; Scaglione F; Derendorf H
    Int J Antimicrob Agents; 2010 May; 35(5):431-8. PubMed ID: 20219329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
    Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Rubino CM; Korth-Bradley JM; Babinchak T; Ellis-Grosse E
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
    Lepe JA; García-Cabrera E; Gil-Navarro MV; Aznar J
    Rev Esp Quimioter; 2012 Jun; 25(2):134-8. PubMed ID: 22707102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
    Sprandel KA; Drusano GL; Hecht DW; Rotschafer JC; Danziger LH; Rodvold KA
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):303-9. PubMed ID: 16887471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.
    Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Bhavnani SM; Ellis-Grosse E
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):155-9. PubMed ID: 19150707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
    Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
    Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.
    Lee SY; Kuti JL; Nicolau DP
    J Infect; 2007 May; 54(5):463-8. PubMed ID: 17067681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach.
    Mouton JW; Brown DF; Apfalter P; Cantón R; Giske CG; Ivanova M; MacGowan AP; Rodloff A; Soussy CJ; Steinbakk M; Kahlmeter G
    Clin Microbiol Infect; 2012 Mar; 18(3):E37-45. PubMed ID: 22264314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections.
    Kuti JL; Ong C; Lo M; Melnick D; Soto N; Nicolau DP
    Int J Antimicrob Agents; 2006 Jul; 28(1):62-8. PubMed ID: 16759839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
    Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interpretive reading of the antibiogram: a clinical necessity].
    Cantón R
    Enferm Infecc Microbiol Clin; 2010; 28(6):375-85. PubMed ID: 20381926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring of antibiotic treatment of patient with a severe bacterial infection].
    Aubert G; Carricajo A
    Ann Fr Anesth Reanim; 2004 Jul; 23(7):704-13. PubMed ID: 15324959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.